232,233 GLP-1 inhibits the release of glucagon from -cells through multiple mechanisms
Notably, reductions in eGFR slope [53] and UACR [54,55] were more pronounced in people with type 2 diabetes mellitus, suggesting additional kidney-protective mechanisms beyond hemodynamic improvements and albuminuria reduction
Beside the insulinotropic effects, GLP-1 has been associated with numerous regulatory and protective effects
Their use is rising rapidly, and with good reason: These medications have been shown to reduce blood sugar, improve fatty liver, GERD, sleep apnea, osteoarthritis, blood pressure, triglycerides, major adverse cardiovascular events, and even show potential benefits for conditions like alcohol use disorder (Mozaffarian et al., 2025
This isn't an accusation that the person doesn't exist